Company patents
GlaxoSmithKline Biologicals SA
GlaxoSmithKline Biologicals SA's patent strategy reveals a surprising and consistent decline across its core pharma_biotech categories, with Pharmaceutical Preparations dropping by 57.1% in 2025 and Peptides & Proteins by 32.3% in the same year, indicating a significant shift in priorities away from these historically dominant areas. While Fermentation & Biosynthesis showed rapid growth of 500.0% in 2024, its subsequent decline to 0 patents so far in 2026 suggests a volatile or short-lived focus in this emerging area.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
277 US filings (since 2023) · 5 categories · 13 themes
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Modifying microorganisms, plant cells, or animal cells through genetic engineering to enhance or enable the biosynthesis of target compounds, often involving metabolic pathway engineering.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Developing advanced bioreactor designs, fermentation strategies, and downstream processing techniques to optimize yield, purity, and efficiency of biotechnological production.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Patents
Showing 1-10 of 462